Table 5.
Univariate analysis of clinical variables for 12-month progression-free survival and overall survival
| Univariate PFS12 | Univariate OS | |||
| Variable | HR (95% CI) | P value | HR (95% CI) | P value |
| Age (continuous) | 1.016 (0.991 to 1.042) | 0.20 | 1.010 (0.98 to 1.04) | 0.47 |
| Gender | ||||
| Male | 1 | 1 | ||
| Female | 1.074 (0.663 to 1.739) | 0.77 | 1.105 (0.65 to 1.88) | 0.71 |
| Primary site | ||||
| Rectum | 1 | 1 | ||
| Colon | 1.567 (0.901 to 2.727) | 0.11 | 1.193 (0.65 to 2.17) | 0.56 |
| Laterality | ||||
| Right-sided | 1 | 1 | ||
| Left-sided | 1.114 (0.632 to 1.965) | 0.71 | 1.373 (0.65 to 2.17) | 0.34 |
| Number of metastatic sites | ||||
| 1 | 1 | 1 | ||
| 2 | 1.277 (0.736 to 2.217) | 0.38 | 1.265 (0.67 to 2.40) | 0.47 |
| 3 or more | 1.750 (0.910 to 3.367) | 0.09 | 2.942 (1.463 to 5.915) | 0.002 |
| ECOG | ||||
| 0 | 1 | 1 | ||
| 1 | 1.037 (0.550 to 1.955) | 0.91 | 1.178 (0.57 to 2.43) | 0.66 |
| 2 | 1.154 (0.418 to 3.187) | 0.78 | 1.100 (0.36 to 3.30) | 0.87 |
| CEA basal | ||||
| ≤ULN | 1 | 1 | ||
| ≥ULN | 1.064 (0.482 to 2.351) | 0.87 | 1.151 (0.49 to 2.70) | 0.75 |
| LDH basal | ||||
| ≤ULN | 1 | 1 | ||
| ≥ULN | 1.173 (0.709 to 1.940) | 0.53 | 1.157 (0.66 to 2.02) | 0.61 |
| β2 microglobulin basal | ||||
| ≥ULN | 1 | 1 | ||
| ≤ULN | 1.281 (0.603 to 2.722) | 0.52 | 1.241 (0.58 to 2.67) | 0.58 |
P-values numbers marked in bold indicate those that are lower than 0.05.
CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; OS, overall survival; PFS12, 12-month progression-free survival; p-values in bold, indicate those that are lower than 0.05; ULN, upper limit of the normal range.